

Halfdan Sorbye

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5809200/publications.pdf>

Version: 2024-02-01

86
papers

6,703
citations

159585

30
h-index

76900

74
g-index

87
all docs

87
docs citations

87
times ranked

7452
citing authors

#	ARTICLE	IF	CITATIONS
1	ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours. <i>Journal of Neuroendocrinology</i> , 2022, 34, e13040.	2.6	12
2	The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms. <i>Endocrine-Related Cancer</i> , 2022, 29, 1-14.	3.1	62
3	Survival According to Primary Tumor Location, Stage, and Treatment Patterns in Locoregional Gastroenteropancreatic High-grade Neuroendocrine Carcinomas. <i>Oncologist</i> , 2022, 27, 299-306.	3.7	14
4	Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer. <i>Cancer Treatment and Research Communications</i> , 2022, 31, 100517.	1.7	0
5	KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 826073.	2.8	15
6	Volumetric parameters from [¹⁸ F]FDG PET/CT predicts survival in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms. <i>Journal of Neuroendocrinology</i> , 2022, 34, .	2.6	12
7	Plasma protein biomarkers for the detection of pancreatic neuroendocrine tumors and differentiation from small intestinal neuroendocrine tumors. <i>Journal of Neuroendocrinology</i> , 2022, 34, .	2.6	4
8	A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations. <i>Neuroendocrinology</i> , 2021, 111, 883-894.	2.5	54
9	A Plasma Protein Biomarker Strategy for Detection of Small Intestinal Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2021, 111, 840-849.	2.5	8
10	Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine–non–neuroendocrine neoplasms. <i>Journal of Neuroendocrinology</i> , 2021, 33, e12967.	2.6	23
11	Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine?. <i>Gut</i> , 2021, 70, 1768-1781.	12.1	28
12	Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer. <i>International Journal of Cancer</i> , 2021, 149, 1385-1397.	5.1	10
13	Repeat sequential oxaliplatin-based chemotherapy (FLOX) and nivolumab versus FLOX alone as first-line treatment of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC): Initial results from the randomized METIMMOX study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3556-3556.	1.6	9
14	Quality of Life in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy”The Randomized NORDIC9-Study. <i>Cancers</i> , 2021, 13, 2604.	3.7	13
15	Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. <i>Acta Oncologica</i> , 2021, 60, 931-941.	1.8	32
16	Abstract 522: Immunogenic chemotherapy and immune checkpoint inhibition (ICI) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC): Biomarkers indicative of durable treatment response. , 2021, , .		0
17	Feminizing adrenal tumor identified by plasma steroid profiling. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2021, 2021, .	0.5	1
18	Prospective Study of Chromogranin A as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2020, 110, 217-224.	2.5	25

#	ARTICLE	IF	CITATIONS
19	Survival and costs of colorectal cancer treatment and effects of changing treatment strategies: a model approach. <i>European Journal of Health Economics</i> , 2020, 21, 321-334.	2.8	10
20	Molecular characterization of a large unselected cohort of metastatic colorectal cancers in relation to primary tumor location, rare metastatic sites and prognosis. <i>Acta OncolÃ³gica</i> , 2020, 59, 417-426.	1.8	22
21	Metastatic colorectal carcinomas with high SATB2 expression are associated with better prognosis and response to chemotherapy: a population-based Scandinavian study. <i>Acta OncolÃ³gica</i> , 2020, 59, 284-290.	1.8	11
22	Patient reported symptoms, coping and quality of life during somatostatin analogue treatment for metastatic small-intestinal neuroendocrine tumours. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 188.	2.4	7
23	Candidate protein biomarkers in pancreatic neuroendocrine neoplasms grade 3. <i>Scientific Reports</i> , 2020, 10, 10639.	3.3	8
24	Feasibility of switching to S-1 after other fluoropyrimidine-related cardiotoxicity during chemotherapy for solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 7037-7037.	1.6	2
25	PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3). <i>Endocrine-Related Cancer</i> , 2020, 27, R67-R77.	3.1	79
26	Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 376-388.	8.1	43
27	Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3). <i>Neuroendocrinology</i> , 2019, 108, 54-62.	2.5	62
28	Survival according to mutations in BRAF, KRAS, or microsatellite instability (MSI-H) after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastases from colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3565-3565.	1.6	2
29	Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study. <i>Endocrine-Related Cancer</i> , 2019, 26, 227-239.	3.1	114
30	Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3). <i>Medical Oncology</i> , 2018, 35, 47.	2.5	13
31	Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases. <i>Cancer</i> , 2018, 124, 807-815.	4.1	169
32	Treatment-related survival associations of claudin-2 expression in fibroblasts of colorectal cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 395-405.	2.8	10
33	The Problem of High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 683-698.	3.2	58
34	Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome. <i>British Journal of Cancer</i> , 2018, 118, 1609-1616.	6.4	47
35	Prognostic significance of SATB1 expression in metastatic colorectal cancer: A Nordic prospective cohort study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 707-707.	1.6	0
36	Expression of podocalyxin-like protein and epidermal growth factor receptor in metastatic colorectal cancer: Prognostic impact and relationship with response to cetuximab.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15587-e15587.	1.6	0

#	ARTICLE	IF	CITATIONS
37	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology - Diagnosis and Prognostic Stratification. <i>Neuroendocrinology</i> , 2017, 105, 196-200.	2.5	178
38	Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study. <i>British Journal of Cancer</i> , 2017, 116, 1271-1278.	6.4	55
39	Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status. <i>European Journal of Cancer</i> , 2017, 81, 26-35.	2.8	13
40	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Chemotherapy. <i>Neuroendocrinology</i> , 2017, 105, 281-294.	2.5	94
41	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents. <i>Neuroendocrinology</i> , 2017, 105, 266-280.	2.5	122
42	Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9. <i>BMC Cancer</i> , 2017, 17, 548.	2.6	13
43	Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian) Tj ETQq1 1 0.784314 rgBT /Overlock 10 controlled trial. <i>BMC Surgery</i> , 2017, 17, 94.	1.3	84
44	Pre-planned safety analysis of NORDIC 9: A randomized trial comparing full dose monotherapy (S-1) with reduced dose combination therapy (S-1/oxaliplatin) in older chemo-naïve patients with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 10032-10032.	1.6	1
45	High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer. <i>PLoS ONE</i> , 2017, 12, e0182512.	2.5	27
46	Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma. <i>PLoS ONE</i> , 2017, 12, e0187667.	2.5	24
47	Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review. <i>Acta Oncol</i> , 2016, 55, 881-885.	1.8	8
48	Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases. <i>International Journal of Cancer</i> , 2016, 139, 647-656.	5.1	79
49	A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. <i>Journal of Controlled Release</i> , 2016, 243, 172-181.	9.9	332
50	Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer. <i>European Journal of Cancer</i> , 2016, 63, 11-24.	2.8	73
51	Drug costs and benefits of medical treatments in high-unmet need solid tumours in the Nordic countries. <i>Journal of Cancer Policy</i> , 2016, 7, 12-22.	1.4	4
52	Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study. <i>Annals of Surgical Oncology</i> , 2016, 23, 1721-1728.	1.5	73
53	Ultrasound and microbubble enhanced treatment of inoperable pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15703-e15703.	1.6	2
54	Intra-individual genetic heterogeneity among liver metastases in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 555-555.	1.6	1

#	ARTICLE	IF	CITATIONS
55	Intra-patient Inter-metastatic Genetic Heterogeneity in Colorectal Cancer as a Key Determinant of Survival after Curative Liver Resection. <i>PLoS Genetics</i> , 2016, 12, e1006225.	3.5	64
56	TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: A potential novel approach to the treatment of metastatic colorectal cancer. <i>Oncotarget</i> , 2016, 7, 59441-59457.	1.8	7
57	Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer. <i>Oncotarget</i> , 2016, 7, 75013-75022.	1.8	61
58	Predictive factors for time to recurrence, treatment and post-recurrence survival in patients with initially resected colorectal liver metastases. <i>World Journal of Surgical Oncology</i> , 2015, 13, 328.	1.9	29
59	Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab. <i>International Journal of Cancer</i> , 2015, 137, 2470-2477.	5.1	8
60	Reply to Letter. <i>Annals of Surgery</i> , 2015, 261, e29.	4.2	0
61	High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort. <i>PLoS ONE</i> , 2015, 10, e0131046.	2.5	91
62	Modeling and Validating the Cost and Clinical Pathway of Colorectal Cancer. <i>Medical Decision Making</i> , 2015, 35, 255-265.	2.4	12
63	Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983. <i>European Journal of Cancer</i> , 2015, 51, 2708-2717.	2.8	72
64	C-reactive protein and interleukin-6 as markers of systemic inflammatory response and as prognostic factors for metastatic colorectal cancer. Data from the randomized phase III NORDIC-VII study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3548-3548.	1.6	0
65	Gastroenteropancreatic high-grade neuroendocrine carcinoma. <i>Cancer</i> , 2014, 120, 2814-2823.	4.1	277
66	Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. <i>Acta Oncologica</i> , 2014, 53, 1284-1297.	1.8	99
67	Recurrence Patterns After Resection of Liver Metastases from Colorectal Cancer. <i>Recent Results in Cancer Research</i> , 2014, 203, 243-252.	1.8	20
68	Plasma YKL-40 in Patients with Metastatic Colorectal Cancer Treated with First Line Oxaliplatin-Based Regimen with or without Cetuximab: RESULTS from the NORDIC VII Study. <i>PLoS ONE</i> , 2014, 9, e87746.	2.5	18
69	Digitalized multiparametric analyses of tumor stroma for identification of low perivascular PDGFR expression and low vessel density as independent prognosis markers for stage IV CRC.. <i>Journal of Clinical Oncology</i> , 2014, 32, e14525-e14525.	1.6	0
70	Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 1208-1215.	10.7	1,017
71	Plasma levels of TIMP-1 in chemo-naïve patients with metastatic colorectal cancer treated with first-line FLOX with or without cetuximab: Results from the Nordic VII Study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 392-392.	1.6	0
72	Plasma TIMP-1 in patients with metastatic colorectal cancer treated with first-line oxaliplatin-based therapy with or without cetuximab: Results from the Nordic VII study.. <i>Journal of Clinical Oncology</i> , 2013, 31, e14710-e14710.	1.6	0

#	ARTICLE	IF	CITATIONS
73	Prognostic significance of tumor stromal and epithelial claudin 2 in metastatic colorectal cancer.. Journal of Clinical Oncology, 2013, 31, 3597-3597.	1.6	0
74	Tumor perivascular PDGFBR as an independent prognostic factor in metastatic colorectal cancer.. Journal of Clinical Oncology, 2013, 31, 3571-3571.	1.6	0
75	Palliative chemotherapy in elderly patients with metastatic colorectal cancer: Do we know how it should be used?. Acta Oncol ³ gica, 2012, 51, 819-821.	1.8	6
76	Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study. Journal of Clinical Oncology, 2012, 30, 1755-1762.	1.6	482
77	Predictive Factors for the Benefit of Perioperative FOLFOX for Resectable Liver Metastasis in Colorectal Cancer Patients (EORTC Intergroup Trial 40983). Annals of Surgery, 2012, 255, 534-539.	4.2	91
78	EORTC liver metastases intergroup randomized phase III study 40983: Long-term survival results.. Journal of Clinical Oncology, 2012, 30, 3508-3508.	1.6	27
79	Maintenance therapy with biweekly cetuximab (C) in the first-line treatment of metastatic colorectal cancer (mCRC): The NORDIC 7.5 study (NCT00660582), by the Nordic Colorectal Cancer Biomodulation Group.. Journal of Clinical Oncology, 2012, 30, 3538-3538.	1.6	2
80	Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal poorly differentiated neuroendocrine carcinoma: The NORDIC NEC study.. Journal of Clinical Oncology, 2012, 30, 4015-4015.	1.6	5
81	FLOX regimen (5-FU, folinic acid, oxaliplatin) and FLIRI regimen (5-FU, folinic acid, irinotecan) as first-line treatment in metastatic and locally advanced gastric cancer: A randomized phase II study.. Journal of Clinical Oncology, 2012, 30, 71-71.	1.6	1
82	Plasma concentrations of YKL-40 in chemo-naive patients with metastatic colorectal cancer treated with FLOX with or without cetuximab: Results from the NORDIC VII study.. Journal of Clinical Oncology, 2012, 30, 3548-3548.	1.6	0
83	Clinical effect of temozolomide [€] -based chemotherapy in poorly differentiated endocrine carcinoma after progression on first [€] -line chemotherapy. Cancer, 2011, 117, 4617-4622.	4.1	233
84	Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients. Cancer, 2009, 115, 4679-4687.	4.1	128
85	Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet, The, 2008, 371, 1007-1016.	13.7	1,759
86	Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer. Oncotarget, 0, 7, 41948-41958.	1.8	30